ReShape Lifesciences reports FY2023 revenue of $8.7M, down 22.8% as GLP-1 drugs pressure bariatric market

Vyome Holdings, Inc

2024-Q1 EPS reported -$0.09 vs consensus -$946.56 ▲ beat (+100.0%)

FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.
Gross profit $5.5M (63.9% margin vs 60.5% in 2022); sales & marketing expenses cut 46.8% to $7.5M.
Cash $4.5M and debt-free; expects 2024 operating expenses to decrease >50% vs 2023 via further RIF.
Received FDA approval for Lap-Band 2.0 FLEX in Dec 2023; first surgeries completed in Feb 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Vyome Holdings, Inc reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8.7 million. Guidance reaffirmed.

Period: the fourth quarter and fiscal year ended December 31, 2023
Revenue: $8.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue totaled $8.7 million for the year ended December 31, 2023

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-24-004700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.